{"title":"Artificial intelligence performance in pediatric asthma.","authors":"Ece Senbaykal Yigit, Ilke Taskirdi, Idil Akay Haci, Tuba Tuncel","doi":"10.1080/02770903.2025.2531500","DOIUrl":"10.1080/02770903.2025.2531500","url":null,"abstract":"<p><strong>Objective: </strong>Asthma is the most common chronic disease of childhood, characterized by symptoms such as wheezing, shortness of breath, and coughing. With the advancement of technology, artificial intelligence (AI) applications are increasingly being used in various fields, among which ChatGPT is one of the most widely utilized. The aim of this study is to evaluate the reliability, quality, and readability of the answers provided by the ChatGPT-4o application to questions related to pediatric asthma.</p><p><strong>Methods: </strong>The ChatGPT-4o application was used to record answers to 25 of the most frequently asked questions about asthma in children. To determine the quality and reliability of the answers, we used the Global Quality Scale and modified DISCERN tool. We tested readability using seven indices: Automated Readability Index, Flesch Reading Ease Score, Flesch-Kincaid Grade Level (FKGL), Gunning Fog Readability Index, Simple Measure of Gobbledygook, Coleman-Liau Readability Index, and Linsear Write Formula.</p><p><strong>Results: </strong>The answers provided by the ChatGPT-4o application to questions about childhood asthma were found to have good reliability (88% by the first evaluator and 84% by the second evaluator) and high quality (88% by both evaluators). The application scored 10.77 ± 1.58 on the FKGL scale, and in conjunction with the other indices, the results indicated that the answers required a high level of reading proficiency.</p><p><strong>Conclusions: </strong>Artificial intelligence can be a reliable tool for parents in providing information about pediatric asthma. However, these findings suggest that readability issues may hinder the clinical application of AI-generated content in asthma diagnosis and treatment.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1926-1932"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-09-05DOI: 10.1080/02770903.2025.2552737
Aditi Maheshwari, Sajal De
{"title":"Oscillometry-defined small airway dysfunction in steroid-naïve adult bronchial asthma: association with eosinophilic and non-eosinophilic phenotypes.","authors":"Aditi Maheshwari, Sajal De","doi":"10.1080/02770903.2025.2552737","DOIUrl":"10.1080/02770903.2025.2552737","url":null,"abstract":"<p><strong>Objective: </strong>Small airway dysfunction (SAD) is a common feature of bronchial asthma. However, its association with asthma phenotypes remains poorly understood. This study aimed to assess the prevalence of oscillometry-defined SAD in steroid-naïve adult bronchial asthma and to explore its association with asthma phenotypes based on peripheral blood eosinophil count (BEC).</p><p><strong>Methods: </strong>A total of 320 consecutive cases of bronchial asthma patients were enrolled. The severity of impairment in oscillometry parameters was expressed in <i>z</i>-scores. SAD in oscillometry was defined as R5-19 > upper limit of normal and/or X5 < lower limit of normal. The cohort was categorized into eosinophilic asthma (EA) and non-eosinophilic asthma (NEA) using a BEC cutoff of 300 cells/µL.</p><p><strong>Results: </strong>The mean age of the cohort was 37.5 ± 12.5 years, and 58.1% were male. The median BEC was 350 cells/µL. The mean FEV<sub>1</sub> was 66.7 ± 18.4 %predicted. Oscillometry-defined SAD was observed in 54.4% (95% CI: 48.1-59.4). Patients with SAD exhibited significantly lower spirometric indices compared to those without SAD. The proportion of EA was 58.4% (95% CI: 53.4-64.7). Spirometric parameters did not differ significantly between the EA and NEA. The severity of impairment in R5 and X5 was less in EA compared to NEA, though the difference was not statistically significant. The proportion of impaired R5-19 was significantly less in EA than NEA (47.6% vs. 57.9%; <i>p</i> = .04).</p><p><strong>Conclusions: </strong>Half of steroid-naïve bronchial asthma patients exhibited SAD at the time of diagnosis. NEA phenotypes are associated with higher impairment in oscillometry.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1995-2001"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-07-31DOI: 10.1080/02770903.2025.2531497
Lianqi Peng, Mi Li, Lijun Xiao, Liping Lei, Wenke Zhou, Yu Ye, Bo Xiao, Dong Yao, Biwen Mo
{"title":"The impact of m6A methyltransferase <i>METTL3</i> on airway remodeling in bronchial asthma.","authors":"Lianqi Peng, Mi Li, Lijun Xiao, Liping Lei, Wenke Zhou, Yu Ye, Bo Xiao, Dong Yao, Biwen Mo","doi":"10.1080/02770903.2025.2531497","DOIUrl":"10.1080/02770903.2025.2531497","url":null,"abstract":"<p><strong>Background: </strong>Methyltransferase-like 3 (<i>METTL3</i>) is known to play a role in asthma airway remodeling and cell proliferation. Adenylate kinase 4 (AK4) regulates the proliferation of pulmonary artery smooth muscle cells and exerts its effects through the protein kinase B (AKT) pathway. However, the role of <i>METTL3</i> and AK4-AKT in bronchial smooth muscle cells remains unclear.</p><p><strong>Methods: </strong>Systemic <i>METTL3</i> knockout mice and a mouse model of asthma were established. Airway remodeling was assessed using pulmonary function tests, histopathological staining, and Western blot analysis. RNA sequencing (RNA-seq) was performed to detect changes in gene expression following <i>METTL3</i> knockdown. The 5-ethynyl-2'-deoxyuridine (EdU) assay was used to evaluate cell proliferation. Finally, the expression levels of relevant proteins were validated by Western blotting.</p><p><strong>Results: </strong>Compared with the control model group, the <i>METTL3</i> knockout group showed significantly reduced inflammatory cell infiltration, decreased collagen fiber deposition, and attenuated airway smooth muscle hyperplasia. RNA-seq revealed that the expression of numerous proliferation-related genes, including AK4, was upregulated following <i>METTL3</i> knockdown. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis indicated that these genes were primarily enriched in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. The EdU assay demonstrated that <i>METTL3</i> knockdown inhibited cell proliferation. Western blot validation showed increased AK4 expression in lung tissues of the <i>METTL3</i> knockout group compared to the control group, while phosphorylated AKT (p-AKT) levels were reduced.</p><p><strong>Conclusions: </strong><i>METTL3</i> knockout inhibits airway smooth muscle hyperplasia and alleviates airway remodeling in asthma. This effect may be mediated through the regulation of AK4 and the AKT signaling pathway.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1912-1925"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-08-20DOI: 10.1080/02770903.2025.2546348
Jefferson Antonio Buendía, Diana Guerrero Patiño, Juan Antonio Buendia Sanchez
{"title":"Montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: cost-utility analysis.","authors":"Jefferson Antonio Buendía, Diana Guerrero Patiño, Juan Antonio Buendia Sanchez","doi":"10.1080/02770903.2025.2546348","DOIUrl":"10.1080/02770903.2025.2546348","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the cost-utility of Mon and Flu versus Flu monotherapy in children with CVA in Colombia.</p><p><strong>Materials: </strong>We simulated a hypothetical cohort of 10,000 pediatric patients diagnosed with CVA, reflecting the typical clinical profile in Colombia. Cost-effectiveness was evaluated at a willingness-to-pay (WTP) value of US$5180. This analysis used QALYs and costs from a third-payer perspective over a 5-year time horizon.</p><p><strong>Results: </strong>The combination of Mon and Flu is not cost-effective since the incremental cost-utility ratio is greater than the willingness to pay per QALY in Colombia (USD 55,547 vs. USD 5180). The cost of Mon has the greatest influence on cost effectiveness, if the cost per dose of Mon 5 mg is less than US$ 0.034, the combination of Mon and Flu will be cost-effective at WTP of US$ 5180.</p><p><strong>Conclusions: </strong>The combination of Mon and Flu is not cost-effective for the management of CVA in children in Colombia, given the current WTP threshold. To enhance the cost-effectiveness of this combination therapy, efforts should focus on reducing the price of Mon and further optimizing its clinical use.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1970-1977"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-07-04DOI: 10.1080/02770903.2025.2526384
Islam Ahmed Abdelmawgood, Mohamed A Kotb, Bassam Waleed Ebeed, Hassan Samy Hassan Eltras, Abeer Mahmoud Badr, Noha A Mahana, Ayman Saber Mohamed, Lamiaa Goda, Marina Lotfy Khalaf, Ahmed M Sayed, Rawan G Zahran, Menna S Abdelazeem, Seif H Eltaweel, Sohaib Ali Ramadan, Bahaa Sharaf, Abdulrahman Adel, Hamid Ashry, Hadeer Hesham Abdelfattah
{"title":"2-Hydroxychalcone attenuates airway inflammation, oxidative stress, and NF-κB activation in ovalbumin-induced asthma model.","authors":"Islam Ahmed Abdelmawgood, Mohamed A Kotb, Bassam Waleed Ebeed, Hassan Samy Hassan Eltras, Abeer Mahmoud Badr, Noha A Mahana, Ayman Saber Mohamed, Lamiaa Goda, Marina Lotfy Khalaf, Ahmed M Sayed, Rawan G Zahran, Menna S Abdelazeem, Seif H Eltaweel, Sohaib Ali Ramadan, Bahaa Sharaf, Abdulrahman Adel, Hamid Ashry, Hadeer Hesham Abdelfattah","doi":"10.1080/02770903.2025.2526384","DOIUrl":"10.1080/02770903.2025.2526384","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a pulmonary disorder marked by limited lung function and a noticeable infiltrate of inflammatory cells. Chalcones are commonly found in food plants and are regarded as precursors of flavonoids. Moreover, they can also be synthesized by chemical processes in controlled laboratory conditions. 2-Hydroxychalcone (2HC) has been associated with several biological functions, such as antioxidant, anti-inflammatory, antidiabetic, and anticancer properties. However, we have yet to study its potential for treating asthma. This study aimed to investigate the inhibitory effects of 2HC on allergic asthma.</p><p><strong>Methods: </strong>We established a mouse model of asthma by subjecting BALB/c mice to ovalbumin (OVA) exposure and sensitization. We conducted a study to examine the impact of 2HC on airway inflammation, the infiltration of inflammatory cells, oxidative stress, excessive mucus production, immunoglobulin E (IgE) levels, and the production of IL-4 and IL-1β. In addition, NF-κB expression was quantified using ELISA and immunohistochemistry (IHC).</p><p><strong>Results: </strong>The administration of 2HC resulted in a considerable reduction in lung oxidative stress, infiltration of inflammatory cells, levels of IgE, IL-4, and IL-1β, production of mucus, and activation of NF-κB.</p><p><strong>Conclusion: </strong>Our findings showed that 2HC is anti-inflammatory and antioxidant, suggesting that it may be useful in treating asthma by blocking NF-κB activation.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1880-1892"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-07-31DOI: 10.1080/02770903.2025.2531501
Kurt Gehlsen, Angelica Carrasco, Jillian Hooghius, Stephen Pyles
{"title":"Neuromodulation for the treatment of moderate to severe asthma - a pilot first-in-human clinical study.","authors":"Kurt Gehlsen, Angelica Carrasco, Jillian Hooghius, Stephen Pyles","doi":"10.1080/02770903.2025.2531501","DOIUrl":"10.1080/02770903.2025.2531501","url":null,"abstract":"<p><strong>Objective: </strong>This was a small, uncontrolled, first-in-human clinical study that evaluated the safety and efficacy of neuromodulation in patients with moderate to severe asthma.</p><p><strong>Methods: </strong>Patients diagnosed with chronic intractable pain and moderate or severe asthma on daily asthma medications were tested and subsequently implanted with a permanent spinal cord stimulator. Patients were followed for 12 months and monitored for changes in medication use, asthma control scores, quality of life, exacerbations, ER visits and hospitalizations.</p><p><strong>Results: </strong>11 patients were enrolled, 9 with asthma, and 2 with asthma plus COPD. 91% of patients achieved <i>a</i> > 50% reduction in all asthma medication usage. For all patients enrolled there was an 88% reduction in all asthma medication use and for patients with asthma alone, there was a 98% reduction in all medication use. 100% of enrolled patients reported an Asthma Control Test (ACT) >19 with improved breathing, no wheezing, no chest tightness, and no exacerbations (average increase of 13.3 points). 100% of the enrolled patients reported an improvement in quality of life with an average increase of 3.4 points using the Asthma Quality of Life Questionnaire (AQLQ). No ER visits or hospitalizations were reported due to asthma. There were no adverse events reported.</p><p><strong>Conclusions: </strong>Neuromodulation provided clinically meaningful improvements in asthma symptoms without the need for asthma medications and without adverse events.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1933-1938"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-07-25DOI: 10.1080/02770903.2025.2537406
Kaiwen Zheng, Qin Wang, Linyan Tang, Xing Chen
{"title":"Pediatric chronic cough: Allergies, environmental factors, and asthma-associated inflammation.","authors":"Kaiwen Zheng, Qin Wang, Linyan Tang, Xing Chen","doi":"10.1080/02770903.2025.2537406","DOIUrl":"10.1080/02770903.2025.2537406","url":null,"abstract":"<p><strong>Background: </strong>Chronic cough (CC) is a common respiratory symptom in children, often linked to allergic conditions, environmental exposures, and potentially indicative of underlying asthma.</p><p><strong>Objective: </strong>To investigate the relationships of CC in children with allergic predispositions, environmental exposures, and airway inflammatory markers.</p><p><strong>Methods: </strong>A case-control study was conducted at a tertiary hospital. Data on cough duration, personal and family allergic histories, and environmental exposures were collected. Airway inflammation was assessed using fractional exhaled nitric oxide (FeNO<sub>50</sub>), and lung function was evaluated <i>via</i> spirometry.</p><p><strong>Results: </strong>Children with CC showed a higher prevalence of allergic conditions, including rhinitis (74.77% vs. 24.13%, OR = 9.312, <i>p</i> < 0.0001), food allergy (59.81% vs. 27.59%, OR = 3.907, <i>p</i> = 0.0017), eczema (55.14% vs. 31.03%, OR = 2.731, <i>p</i> = 0.0213), and family history of allergies (71.96% vs. 27.59%, OR = 6.738, <i>p</i> < 0.001). Environmental exposures, such as household smoking (55.14% vs. 20.69%, OR = 4.712, <i>p</i> = 0.001) and mold exposure (28.68% vs. 7.35%, OR = 3.442, <i>p</i> = 0.0251), were more common in the CC group. CC children exhibited elevated FeNO<sub>50</sub> (median: 18 vs. 14 ppb, <i>p</i> = 0.0153) and impaired small airway function (FEF75%pred: 53.84 ± 20.21 vs. 65.07 ± 28.52, <i>p</i> = 0.0170).</p><p><strong>Conclusions: </strong>Pediatric CC is strongly associated with allergic predispositions, environmental exposures, and eosinophilic airway inflammation, potentially reflecting an asthma-related phenotype.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1939-1949"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-08-22DOI: 10.1080/02770903.2025.2548534
Linh-An C Tuong, Allison Ramsey, Sara Patrawala, Richard Kraude, Peter Capucilli, Denise Sanchez-Tejera, S Shahzad Mustafa
{"title":"Inpatient Electronic-Consults for Asthma Hospitalization Improve Outpatient Outcomes.","authors":"Linh-An C Tuong, Allison Ramsey, Sara Patrawala, Richard Kraude, Peter Capucilli, Denise Sanchez-Tejera, S Shahzad Mustafa","doi":"10.1080/02770903.2025.2548534","DOIUrl":"10.1080/02770903.2025.2548534","url":null,"abstract":"<p><strong>Objective: </strong>Asthma exacerbations frequently lead to systemic corticosteroid use, emergency department (ED) visits, and hospitalizations. While specialist care can improve asthma outcomes, a critical gap often exists between inpatient hospitalization and outpatient follow-up. This study measured the clinical impact of an allergy/immunology (A/I) electronic consult (e-consult) for patients hospitalized for asthma exacerbation.</p><p><strong>Methods: </strong>In this quality improvement project, all patients admitted for asthma received an A/I e-consult addressing asthma controller therapy and outpatient follow-up. Clinical outcomes were tracked for the subsequent year. Results are reported with descriptive statistics, and a paired T-test was used to compare groups.</p><p><strong>Results: </strong>133 patients were enrolled; mean age 28.9 ± 23.3 years, 76 (57%) females, 64 (48%) Black, and 36 (27%) Hispanic. 73 (55%) patients were on asthma maintenance therapy, whereas 60 (45%) were on monotherapy with a short-acting beta agonist (SABA). In the year prior to hospital admission, 43 (32%) had been seen in the ED/UC and 73 (55%) had been previously hospitalized. The mean courses of SCS was 2.5 ± 2.2. Following the inpatient e-consult, 77 (58%) followed up as scheduled, and there was a decrease in hospitalization (mean 1.38 ± 0.11 to 0.42 ± 0.10, <i>p</i><.0001), ED/UC visits (mean 1.35 ± 0.23 to 0.70 ± 0.15, <i>p</i>=.0025), and SCS courses (mean 2.74 ± 0.25 to 1.43 ± 0.25, <i>p</i><.0001). An inpatient e-consult improved outcomes regardless of follow-up status for both pediatric and adult patients.</p><p><strong>Conclusion: </strong>Inpatient A/I e-consults for asthma exacerbations decreased SCS use and healthcare utilization, including inpatient hospitalization, in both pediatric and adult patients.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1988-1994"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-11-01Epub Date: 2025-07-10DOI: 10.1080/02770903.2025.2526376
Haochang Wang, Jiapei Wang, Xuanya He
{"title":"The efficacy of dexamethasone compared to prednisone/prednisolone for the management of pediatric patients with acute exacerbation of asthma: a systematic review and meta-analysis.","authors":"Haochang Wang, Jiapei Wang, Xuanya He","doi":"10.1080/02770903.2025.2526376","DOIUrl":"10.1080/02770903.2025.2526376","url":null,"abstract":"<p><strong>Objective: </strong>This updated meta-analysis aimed to investigate the efficacy of dexamethasone compared to prednisone/prednisolone for the management of pediatric patients with acute exacerbation of asthma.</p><p><strong>Data sources: </strong>PubMed, Web of Science, the Cochrane Library, and Scopus were systematically searched from the inception to March 8, 2025.</p><p><strong>Study selections: </strong>Randomized controlled trials comparing the effect of dexamethasone with prednisone/prednisolone on hospital admission, relapse, readmission, length of hospital stay, pediatric respiratory assessment measure (PRAM) score, intensive care unit (ICU) admission, noncompliance, and vomiting among pediatric patients with acute asthma exacerbation were identified. Studies other than randomized controlled trials, studies lacking both groups and those not reporting the outcomes of interest were excluded. A random-effects model was adopted to pool data.</p><p><strong>Results: </strong>Sixteen studies with 1481 individuals in the dexamethasone group and 1436 individuals in the prednisone/prednisolone group were included. No significant differences were found between dexamethasone and prednisone/prednisolone groups in terms of the risk of hospitalization (RR 0.96, 95% CI (0.79, 1.17), I<sup>2</sup> = 0.00%), ICU admission (RR 0.64, 95% CI (0.08, 4.88), I<sup>2</sup> = 0.00%), relapse (RR 0.99, 95% CI (0.71, 1.38), I<sup>2</sup> = 0.00%), hospital readmission (RR 0.90, 95% CI (0.34, 2.35), I<sup>2</sup> = 30.98%), the PRAM score (RR -0.24, 95% CI (-0.54, 0.06), I<sup>2</sup> = 41.30%), the length of hospital stay (RR -2.69 h, 95% CI (-6.91, 1.53), I<sup>2</sup> = 69.50%), and noncompliance (RR 0.47, 95% CI (0.07, 3.01), I<sup>2</sup> = 65.20%). Moreover, dexamethasone decreased the risk of vomiting (RR 0.39, 95% CI (0.25, 0.59), I<sup>2</sup> = 26.62%) compared to prednisone-prednisolone.</p><p><strong>Conclusion: </strong>Dexamethasone was not inferior to prednisolone/prednisone in the management of pediatric asthma exacerbation.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1831-1842"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of AsthmaPub Date : 2025-10-24DOI: 10.1080/02770903.2025.2577637
Feng Yang, Jia Zheng, Meng Gao, Lihua Ning
{"title":"Association Between Social Determinants of Health and Asthma: A Cross-Sectional Analysis Based on NHANES Data.","authors":"Feng Yang, Jia Zheng, Meng Gao, Lihua Ning","doi":"10.1080/02770903.2025.2577637","DOIUrl":"https://doi.org/10.1080/02770903.2025.2577637","url":null,"abstract":"<p><strong>Introduction: </strong>This study examines the link between social determinants of health (SDoH) and asthma, utilizing data from the National Health and Nutrition Examination Survey (NHANES).</p><p><strong>Methods: </strong>We analyzed 39,340 participants, including 5,645 with asthma and 33,695 without. Multivariable logistic regression assessed the SDoH-asthma relationship, with subgroup analyses for effect modifiers. Machine learning models combining demographic, clinical, and SDoH variables were evaluated using area under the curve (AUC).</p><p><strong>Results: </strong>Asthma was more prevalent among younger individuals (mean age: 45.11 years), females (58%), and those with significant differences in BMI, education, marital status, and race (all P < 0.001). Unadjusted models showed a 5.5% increased asthma risk per SDoH index unit (OR = 1.055, P < 0.001), remaining significant after demographic and clinical adjustments (Model 2: OR = 1.045, Model 3: OR = 1.039). Stronger SDoH-asthma associations were found among smokers (OR = 1.08) and diabetics (OR = 1.12), but not in participants with higher education (OR = 1.00). Model 3, including SDoH variables, demonstrated superior predictive performance (training AUC = 0.779) with minimal generalizability loss (ΔAUC = 0.206).</p><p><strong>Conclusion: </strong>SDoH is an independent risk factor for asthma, particularly among smokers, diabetics, and individuals with less education. Incorporating SDoH into predictive models enhances performance and offers insights for clinical and policy interventions.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-11"},"PeriodicalIF":1.3,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}